p53, p63 and p73 in the wonderland of S. cerevisiae

Since its discovery in 1979, p53 has been on the forefront of cancer research. It is considered a master gene of cancer suppression and is found mutated in around 50% of all human tumors. In addition, the progressive identification of p53-related transcription factors p63 and p73 as well as their multiple isoforms have added further layers of complexity to an already dense network. Among the numerous models used to unravel the p53 family mysteries, S. cerevisiae has been particularly useful. This seemingly naive model allows the expression of a functional human p53 and thus the assessment of p53 intrinsic transcriptional activity. The aim of this article is to review the various contributions that the budding yeast has made to the understanding of p53, p63 and p73 biology and to envision new possible directions for yeast-based assays in the field of cancer as well as other p53-family-related diseases.

• Publication year

  2017

• Venue

  OncoTarget

• Publication date

  2017-06-16

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.18632/oncotarget.18506PMID 28915717PMCID 5593689
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• p53 family interactions and yeast: together in anticancer therapy.

  2016cited by this paper
• The dominant-negative interplay between p53, p63 and p73: A family affair

  2016influential reference
• Setdb1, a novel interactor of ΔNp63, is involved in breast tumorigenesis

  2016cited by this paper
• Comparison of TP53 mutations screening by functional assay of separated allele in yeast and next-generation sequencing in myelodysplastic syndromes.

  2015cited by this paper
• Studying p53 family proteins in yeast: induction of autophagic cell death and modulation by interactors and small molecules.

  2015cited by this paper
• A tryptophanol-derived oxazolopiperidone lactam is cytotoxic against tumors via inhibition of p53 interaction with murine double minute proteins.

  2015cited by this paper
• The BM2 protein of influenza B virus interacts with p53 and inhibits its transcriptional and apoptotic activities

  2015cited by this paper
• Evolution of p53 Transactivation Specificity through the Lens of a Yeast-Based Functional Assay

  2015cited by this paper
• Reactivation of wild-type and mutant p53 by tryptophanolderived oxazoloisoindolinone SLMP53-1, a novel anticancer small-molecule

  2015cited by this paper
• Re-engineered p53 Activates Apoptosis In Vivo and Causes Primary Tumor Regression in A Dominant Negative Breast Cancer Xenograft Model

  2014cited by this paper
• TP63 and TP73 in cancer, an unresolved “family” puzzle of complexity, redundancy and hierarchy

  2014cited by this paper
• ΔN-P63α and TA-P63α exhibit intrinsic differences in transactivation specificities that depend on distinct features of DNA target sites

  2014cited by this paper
• MDM2’s social network

  2014cited by this paper
• Abstract 3402: ΔN-p63α and TA-p63α exhibit intrinsic differences in transactivation specificities that depend on distinct features of DNA target sites

  2014cited by this paper
• Prion-like aggregation of mutant p53 in cancer.

  2014cited by this paper
• Novel simplified yeast‐based assays of regulators of p53–MDMX interaction and p53 transcriptional activity

  2013cited by this paper
• Validation of a yeast functional assay for p53 mutations using clonal sequencing

  2013cited by this paper
• p53 death signal is mainly mediated by Nuc1(EndoG) in the yeast Saccharomyces cerevisiae.

  2013influential reference
• Mutational landscape and significance across 12 major cancer types

  2013cited by this paper
• Α-mangostin and gambogic acid as potential inhibitors of the p53-MDM2 interaction revealed by a yeast approach.

  2013cited by this paper
• Discovery of a new small-molecule inhibitor of p53-MDM2 interaction using a yeast-based approach.

  2013cited by this paper
• p53 Aggregates Penetrate Cells and Induce the Co-Aggregation of Intracellular p53

  2013cited by this paper
• EEC‐ and ADULT‐Associated TP63 Mutations Exhibit Functional Heterogeneity Toward P63 Responsive Sequences

  2013cited by this paper
• p53 Transactivation and the Impact of Mutations, Cofactors and Small Molecules Using a Simplified Yeast-Based Screening System

  2011cited by this paper
• The p53 family: guardians of maternal reproduction

  2011cited by this paper
• Dominant-Negative Features of Mutant TP53 in Germline Carriers Have Limited Impact on Cancer Outcomes

  2011cited by this paper
• Gamete formation resets the aging clock in yeast.

  2011influential reference
• p53 Isoforms: An Intracellular Microprocessor?

  2011cited by this paper
• Gametogenesis Eliminates Age-Induced Cellular Damage and Resets Life Span in Yeast

  2011cited by this paper
• An invertebrate mdm homolog interacts with p53 and is differentially expressed together with p53 and ras in neoplastic Mytilus trossulus haemocytes.

  2010cited by this paper
• Identification and characterization of the novel protein CCDC106 that interacts with p53 and promotes its degradation

  2010cited by this paper
• Interaction of TAp73 and breast cancer-associated gene 3 enhances the sensitivity of cervical cancer cells in response to irradiation-induced apoptosis.

  2010cited by this paper
• The first 30 years of p53: growing ever more complex

  2009cited by this paper
• Stxbp4 Regulates ΔNp63 Stability by Suppression of RACK1-Dependent Degradation

  2009cited by this paper
• Selection of cell death‐deficient p53 mutants in Saccharomyces cerevisiae

  2009cited by this paper
• Determination of optimal conditions for analysis of p53 status in leukemic cells using functional analysis of separated alleles in yeast

  2009cited by this paper
• BAF60a Interacts with p53 to Recruit the SWI/SNF Complex*

  2008cited by this paper
• Reconstitution of Mdm2-Dependent Post-Translational Modifications of p53 in Yeast

  2008cited by this paper
• TATA binding protein associated factor 3 (TAF3) interacts with p53 and inhibits its function

  2008cited by this paper
• Human p53 induces cell death and downregulates thioredoxin expression in Saccharomyces cerevisiae.

  2008cited by this paper
• Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers.

  2007cited by this paper
• Transcriptional Functionality of Germ Line p53 Mutants Influences Cancer Phenotype

  2007cited by this paper
• p63-Associated Disorders

  2007cited by this paper
• Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database

  2007cited by this paper
• Identification of protein kinase A catalytic subunit β as a novel binding partner of p73 and regulation of p73 function

  2007cited by this paper
• Recognition of RNA by the p53 tumor suppressor protein in the yeast three-hybrid system.

  2006cited by this paper
• Evidence for the interaction of the regulatory protein Ki-1/57 with p53 and its interacting proteins.

  2006cited by this paper
• p19ras Interacts with and Activates p73 by Involving the MDM2 Protein*♦

  2006cited by this paper
• Protein stability and function of p73 are modulated by a physical interaction with RanBPM in mammalian cultured cells

  2005cited by this paper
• A human protein-protein interaction network: a resource for annotating the proteome.

  2005cited by this paper
• Functional analysis of p53 gene and the prognostic impact of dominant‐negative p53 mutation in endometrial cancer

  2005cited by this paper
• Identification of Protein Kinase A Catalytic Subunit β as a Novel Binding Partner of p73 and Regulation of p73 Function*

  2005cited by this paper
• Involvement of human p53 in induced intrachromosomal recombination in Saccharomyces cerevisiae.

  2004cited by this paper
• Loss of p53 transcriptional activity in hepatocellular carcinoma evaluated by yeast-based functional assay: comparison with p53 immunohistochemistry.

  2004cited by this paper
• Isolation of Temperature-sensitive p53 Mutations from a Comprehensive Missense Mutation Library*

  2004cited by this paper
• Involvement of human p 53 in induced intrachromosomal recombination in Saccharomyces cerevisiae

  2004cited by this paper
• Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity

  2003cited by this paper
• Function of p73, not of p53, is inhibited by the physical interaction with RACK1 and its inhibitory effect is counteracted by pRB

  2003cited by this paper
• Understanding the function–structure and function–mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis

  2003cited by this paper
• Characterization of the p53 mutants ability to inhibit p73β transactivation using a yeast-based functional assay

  2003cited by this paper
• Tumour p53 mutations exhibit promoter selective dominance over wild type p53

  2002cited by this paper
• Physical Interaction of p73 with c-Myc and MM1, a c-Myc-binding Protein, and Modulation of the p73 Function*

  2002cited by this paper
• Analysis of molecular interactions of the p53-family p51(p63) gene products in a yeast two-hybrid system: homotypic and heterotypic interactions and association with p53-regulatory factors.

  2001cited by this paper
• Translational control of human p53 expression in yeast mediated by 5'-UTR-ORF structural interaction.

  2001cited by this paper
• Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants

  2001cited by this paper
• p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements

  2001cited by this paper
• p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay

  2001influential reference
• Functional inactivation of p73, a homolog of p53 tumor suppressor protein, by human papillomavirus E6 proteins

  2001cited by this paper
• Surfing the p53 network

  2000cited by this paper
• Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme.

  1999cited by this paper
• MBP1: a novel mutant p53-specific protein partner with oncogenic properties

  1999cited by this paper
• Effects of p51/p63 missense mutations on transcriptional activities of p53 downstream gene promoters.

  1999cited by this paper
• p73 Function Is Inhibited by Tumor-Derived p53 Mutants in Mammalian Cells

  1999cited by this paper
• FASAY: a simple functional assay in yeast for identification of p53 mutation in tumors.

  1999cited by this paper
• Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast

  1998influential reference
• Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations

  1998cited by this paper
• Mutation detection by a two-hybrid assay.

  1998cited by this paper
• p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities.

  1998cited by this paper
• Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay

  1998cited by this paper
• Screening the p53 status of human cell lines using a yeast functional assay

  1997cited by this paper
• Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers.

  1997cited by this paper
• Field cancerisation and polyclonal p53 mutation in the upper aero- digestive tract

  1997cited by this paper
• Simple identification of dominant p53 mutants by a yeast functional assay.

  1997cited by this paper
• Dominant-negative p53 mutations selected in yeast hit cancer hot spots.

  1996cited by this paper
• Reverse two-hybrid and one-hybrid systems to detect dissociation of protein-protein and DNA-protein interactions.

  1996cited by this paper
• Mutational analysis of the carboxy-terminal portion of p53 using both yeast and mammalian cell assays in vivo.

  1995cited by this paper
• A simple p53 functional assay for screening cell lines, blood, and tumors.

  1995cited by this paper
• Two cellular proteins that bind to wild-type but not mutant p53.

  1994cited by this paper
• A rapid PCR fidelity assay.

  1994cited by this paper
• Screening patients for heterozygous p53 mutations using a functional assay in yeast

  1993cited by this paper
• Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53

  1993cited by this paper
• Identification of mutations in p53 that affect its binding to SV40 large T antigen by using the yeast two‐hybrid system

  1993cited by this paper
• Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53.

  1992cited by this paper
• Construction of a GAL1-regulated yeast cDNA expression library and its application to the identification of genes whose overexpression causes lethality in yeast.

  1992cited by this paper
• Human p53 inhibits growth in Schizosaccharomyces pombe

  1992cited by this paper
• Human p53 and CDC2Hs genes combine to inhibit the proliferation of Saccharomyces cerevisiae

  1992cited by this paper
• Mammalian p53 can function as a transcription factor in yeast.

  1992cited by this paper
• Identification of p53 as a sequence-specific DNA-binding protein

  1991cited by this paper
• A potential transcriptional activation element in the p53 protein.

  1990cited by this paper
• The ADE2 gene from Saccharomyces cerevisiae: sequence and new vectors.

  1990cited by this paper

• Evolving methodologies for identification and differentiation of regulated cell death modalities.

  2025cites this paper
• The evaluation of the possibility of Li-Fraumeni syndrome in cancer patients in East Azarbaijan Province of Iran

  2023cites this paper
• Programmed cell death detection methods: a systematic review and a categorical comparison

  2022cites this paper
• Selective functional inhibition of a tumor-derived p53 mutant by cytosolic chaperones identified using split-YFP in budding yeast

  2021cites this paper
• p53, A Victim of the Prion Fashion

  2021cites this paper
• Autophagy and glycolysis independently attenuate silibinin-induced apoptosis in human hepatocarcinoma HepG2 and Hep3B cells

  2021cites this paper
• Exploring absent protein function in yeast: assaying post translational modification and human genetic variation

  2021cites this paper
• Homologs of the Tumor Suppressor Protein p53: A Bioinformatics Study for Drug Design.

  2020cites this paper
• Lentivirus-Mediated Overexpression of SIVA-1 Reverses Cisplatin Resistance in Gastric Cancer in vitro

  2020cites this paper
• Biomedical applications of yeasts - a patent view, part two: era of humanized yeasts and expanded applications

  2020cites this paper
• Tumor suppressor protein p53 expressed in yeast can remain diffuse, form a prion, or form unstable liquid-like droplets

  2020cites this paper
• A Humanized Yeast Phenomic Model of Deoxycytidine Kinase to Predict Genetic Buffering of Nucleoside Analog Cytotoxicity

  2019cites this paper
• Modeling human disease in yeast: recreating the PI3K-PTEN-Akt signaling pathway in Saccharomyces cerevisiae

  2019cites this paper
• Dissecting the molecular function of the ubiquitin-like Atg8 during autophagosome biogenesis in S. cerevisiae

  2018cites this paper